Cell therapy using bone marrow stromal cells in chronic paraplegic rats: systemic or local administration?

Area of Science:

• Regenerative Medicine
• Neuroscience
• Cell Therapy

Background:

• Spinal cord injury (SCI) often results in chronic paraplegia with limited functional recovery options.
• Bone marrow stromal cells (BMSC) have shown therapeutic potential in preclinical SCI models.
• The optimal administration route for BMSC in chronic SCI remains unclear.

Purpose of the Study:

• To compare the efficacy of systemic (intravenous) versus local (intracavitary) BMSC administration in a rat model of chronic paraplegia.
• To evaluate functional recovery and histological changes following BMSC treatment.
• To determine if local BMSC delivery enhances spinal cord reconstruction and neuronal differentiation.

Main Methods:

• Adult Wistar rats with complete paraplegia induced by weight-drop impact were used.
• Three months post-injury, animals received either intravenous or intracavitary BMSC injections.
• Functional recovery was assessed using the BBB score, cold spray test, and thigh perimeter measurements.
• Spinal cord tissues were analyzed histologically 6 months post-injection.

Main Results:

• Intravenous BMSC administration showed some functional recovery compared to controls.
• Intracavitary BMSC administration resulted in significantly superior and progressive functional recovery.
• Histological analysis indicated long-term BMSC presence in the injured tissue, with evidence of neuronal differentiation and spinal cord reconstruction.

Conclusions:

• Local administration of BMSC into the traumatic spinal cord cavity is a more effective therapeutic strategy than systemic delivery for chronic paraplegia.
• Intracavitary BMSC promote significant functional recovery and spinal cord tissue regeneration.
• BMSC may facilitate neuronal differentiation and spinal cord reconstruction, offering a promising avenue for SCI treatment.